From wearable to implantable CGM: the connectivity challenge
Continuous Glucose Monitoring (CGM) is central to diabetes care, but traditional systems rely on external transmitters and patches that compromise comfort. A new wave of implantable sensors removes this hardware for a more discreet, user-friendly experience. But moving CGMs under the skin creates new hurdles. Reliable real-time wireless links are harder to achieve, yet essential for patient safety. Devices must also balance strict size constraints, year-long lifetimes, and ultra-low power consumption.
Bluetooth Low Energy (BLE) offers a viable path – enabling direct, low-power communication with smartphones and simplifying the overall system.
Inside, you'll learn:
- First-hand insights from antenna prototypes proven in real-world scenarios.
- Why RF performance fails when antenna, enclosure, and electronics aren’t engineered as an integrated system.
- How accurate tissue models and test environments prevent late-stage setbacks.
- Ways to balance miniaturisation, energy use, and tissue effects
Read more about the challenges, trade-offs, and how these lessons can help de-risk your next active implantable device.
Get your free copy below
(No form-fill required)
Read the e-book
About TTP’s Biosensing team
TTP’s biosensor device development specialists focus on creating advanced wearable and implantable devices, bringing together multidisciplinary expertise to deliver bespoke solutions for the most demanding requirements. From exploring new frontiers to advancing your next breakthrough or accelerating your route to market, we tackle complex technical challenges with scientific and engineering discipline. We identify and mitigate risks early, ensuring outcomes that are both high-impact and centred on the needs of end users. When internal capacity is limited, TTP has the resources and know-how to step in and deliver.
